BioClinica, Inc.

Garry D. Johnson has been appointed senior vice president and chief technology officer at BioClinica, Inc. The newly created position was established to support the company’s growth initiatives and emphasis on IT across the organization. Mr. Johnson will lead the company’s global technology strategy, including developing and implementing BioClinica’s technology plan, overseeing technology investments and ensuring that operational efficiencies are maximized.

Mr. Johnson has more than 15 years of experience leading international technology organizations through the strategic development and execution of IT plans. He most recently served as senior vice president and global chief technology officer for Dendrite International, Inc., where he led a team of 900 technology professionals on three continents. Among his accomplishments was the development of a new CRM solution that gained broad customer acceptance with six migrations in the first 12 months. Prior to Dendrite, Mr. Johnson held leadership positions at Boron Lepore, Inc. (now Cardinal Health) and AlliedSignal, Inc. (now Honeywell).

“Garry is a proven technology leader with the skills to advance BioClinica’s industry-leading position in clinical trial management services. His wealth of industry knowledge and experience make him a valued asset to BioClinica and our global customer base,” said Mark Weinstein, chief executive officer of BioClinica.”